Zenas BioPharma (ZBIO) Corporate presentation summary

Strategic vision and corporate positioning

• Aims to become a global, multi-franchise, fully integrated commercial-stage biopharma company with a robust pipeline in immunology and inflammation (I&I) indications.

• Cash runway extends into 2029, supporting commercialization and pipeline advancement.

• Executive team has deep experience with 70+ IND filings, 30+ BLA/NDA filings, and 30+ commercial launches.

Pipeline and clinical milestones

• Obexelimab: BLA accepted by FDA for IgG4-RD, MAA submission to EMA planned, with U.S. and EU launches expected in 2027 pending approval.

• Orelabrutinib: Phase 3 trials initiated for naSPMS and PPMS, targeting high unmet need in progressive MS.

• ZB021 (oral IL-17 inhibitor): Phase 1 PK and safety data expected by year-end 2026, with patient data in 2027.

• ZB022 (brain-penetrant TYK2 inhibitor) and ZB014 (half-life extended CD19/FcyRIIb mAb): IND-enabling studies ongoing, clinical data expected in 2027.

Obexelimab clinical and commercial highlights

• INDIGO Phase 3 trial in IgG4-RD met primary and all key secondary endpoints, showing a 56% reduction in disease flare risk and significant steroid-sparing benefits.

• Safety profile comparable to placebo, with fewer serious and high-grade adverse events.

• Market research indicates strong physician preference for obexelimab as a first-line therapy, with 47% biologic share and preference for subcutaneous administration.

• U.S. IgG4-RD market estimated at $3B, with significant growth potential as awareness and diagnosis increase.